# IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

> **NCT06790706** · PHASE2 · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 154 (estimated)

## Conditions studied

- Peritoneal Mesothelioma
- Gestational Trophoblastic Tumor
- Thymoma and Thymic Carcinoma
- Anaplastic Thyroid Carcinomas
- Gastroenteropancreatic Neuroendocrine Tumor
- Carcinoid Tumor

## Interventions

- **DRUG:** DOMVANALIMAB + ZIMBERELIMAB
- **DRUG:** DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4

## Key facts

- **NCT ID:** NCT06790706
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-11
- **Final completion:** 2031-06
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06790706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06790706, "IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06790706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*